Cancer Monoclonal Antibodies Market
Global Cancer Monoclonal Antibodies Market Size, Share & Trends Analysis Report, By Type (Naked, Conjugated, and Others), By Application (Breast Cancer, Liver Cancer, Blood Cancer, Brain Cancer, Colorectal Cancer, and Others) and Forecast, 2020-2026
The global cancer monoclonal antibodies market is estimated to grow at a CAGR of 9.8% during the forecast period. The increasing prevalence of cancer and advances in biomedical research are pivotal factors encouraging market growth. As per the World Health Organization (WHO), in 2018, 18.1 million new cancer incidences were reported globally. Globally, in 2018, 43.8 million persons were suffering from cancer who were diagnosed within the last 5 years. Monoclonal antibodies served as one of the established therapeutic strategies for both solid tumors and hematologic malignancies. It is a type of immunotherapy that stimulates the immune system of cancer patients and works to find and attack cancer cells.
Some monoclonal antibodies that are utilized for cancer treatment are known as targeted therapy as it works by finding a specific target on a cancer cell and then attack those cells. However, some monoclonal antibodies also work as immunotherapy to make the immune system respond better which in turn, supports the body to more potentially find and attack cancer cells. Monoclonal antibodies are intravenously administered, and some monoclonal antibody drugs may be utilized along with hormone therapy and chemotherapy.
Some monoclonal antibody drugs that are available with their generic name include trastuzumab (Herceptin), rituximab (Mabthera), pertuzumab (Perjeta), and bevacizumab (Avastin). Trastuzumab is a targeted cancer drug treatment that contains large amounts of a protein known as human epidermal growth factor receptor 2 (HER2). It is used for the treatment of early breast cancer, advanced stomach cancer, and advanced breast cancer. Some stomach and breast cancers have considerable amounts of HER2 that are referred to as HER2 positive cancers, which makes the cancer cells grow and divide. Trastuzumab works by binding to HER2 which thereby stops the growth and division of cancerous cells.
Market Segmentation
The global cancer monoclonal antibodies market is segmented based on type and application. Based on type, the market is classified into naked, conjugated, and others. Based on the application, the market is classified into breast cancer, liver cancer, blood cancer, brain cancer, colorectal cancer, and others.
Naked Monoclonal Antibodies Finds Significant Application in Cancer Treatment
Naked monoclonal antibodies are the most common form of antibodies used for the treatment of cancer. Most naked monoclonal antibodies bind to antigens that are normally multiple on the surface of cancer cells compared to healthy cells. However, some work by binding to antigens on other non-cancerous cells. Some naked monoclonal antibodies stimulate an immune response of cancer patients against cancerous cells by binding to them. For destroying cancerous cells, it works as a marker for the patient’s immune system. A major instance of this kind of monoclonal antibody drug includes alemtuzumab (Campath), indicated for the treatment of patients suffering from chronic lymphocytic leukemia. Additionally, some naked monoclonal antibodies stimulate the patient’s immune response by targeting the immune system checkpoints. Other naked monoclonal antibodies act primarily by binding to and blocking antigens on cancerous cells that support the growth and dispersion of cancer cells. This includes trastuzumab (Herceptin), an antibody-drug against the HER2 protein.
Global Cancer Monoclonal Antibodies Market Share by Type, 2019 (%)
Regional Analysis
Geographically, in 2019, North America held the largest share in the market owing to the increasing prevalence of cancer, significant FDA approvals for monoclonal antibodies. As per the Centers for Disease Control and Prevention (CDC), the number of new cancer incidences in the US is expected to grow from nearly 1.5 million annually in 2010 to 1.9 million annually in 2020. This results in an increasing demand for monoclonal antibody drugs that act as a targeted therapy to destroy cancer cells. Asia-Pacific is estimated to witness potential growth during the forecast period, owing to the rising cancer incidences and potential awareness regarding cancer treatment in the region.
Global Cancer Monoclonal Antibodies Market Growth, by Region 2020-2026
Market Players Outlook
Some prominent players in the market include Amgen Inc., Eli Lilly & Co., F. Hoffman-La Roche AG, Merck & Co., Inc., and Novartis AG. Product launches and partnerships and collaborations are regarded as some potential strategies implemented by the market players to increase their position in the marketplace. For instance, in December 2019, Mylan N.V. and Biocon Ltd. declared the launch of Ogivri (trastuzumab-dkst) in the US. It is biosimilar to Herceptin (trastuzumab). It was the first biosimilar trastuzumab approved by the US FDA for all indications which includes treatment of HER2-overexpressing metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) and breast cancer.
The Report Covers
- Market value data analysis of 2019 and forecast to 2026.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global cancer monoclonal antibodies market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules and Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Amgen, Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Eli Lilly and Co.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. F. Hoffmann-La Roche AG
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Merck & Co., Inc.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Novartis AG
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Cancer Monoclonal Antibodies Market by Type
5.1.1. Naked
5.1.2. Conjugated
5.1.3. Others (Bispecific)
5.2. Global Cancer Monoclonal Antibodies Market by Application
5.2.1. Breast Cancer
5.2.2. Liver Cancer
5.2.3. Blood Cancer
5.2.4. Brain Cancer
5.2.5. Colorectal Cancer
5.2.6. Others
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AbbVie, Inc.
7.2. Amgen, Inc.
7.3. AstraZeneca plc
7.4. Bayer AG
7.5. Biocon, Ltd.
7.6. Bristol Myers Squibb Co.
7.7. Daiichi Sankyo Company, Ltd.
7.8. Eli Lilly and Co.
7.9. F. Hoffmann-La Roche AG
7.10. Genmab A/S
7.11. GlaxoSmithKline plc
7.12. Innate Pharma S.A.
7.13. Johnson & Johnson Services, Inc.
7.14. Merck & Co., Inc.
7.15. Mylan N.V.
7.16. Novartis AG
7.17. Oncologie, Inc.
7.18. Pfizer Inc.
7.19. Spectrum Pharmaceuticals, Inc.
7.20. Takeda Pharmaceutical Co., Ltd.
1. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
2. GLOBAL NAKED MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
3. GLOBAL CONJUGATED MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
4. GLOBAL OTHER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
6. GLOBAL MONOCLONAL ANTIBODIES IN BREAST CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
7. GLOBAL MONOCLONAL ANTIBODIES IN LIVER CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
8. GLOBAL MONOCLONAL ANTIBODIES IN BLOOD CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
9. GLOBAL MONOCLONAL ANTIBODIES IN BRAIN CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
10. GLOBAL MONOCLONAL ANTIBODIES IN COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
11. GLOBAL MONOCLONAL ANTIBODIES IN OTHER CANCER TYPES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
12. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
13. NORTH AMERICAN CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
14. NORTH AMERICAN CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
15. NORTH AMERICAN CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
16. EUROPEAN CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
17. EUROPEAN CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
18. EUROPEAN CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
19. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
20. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
21. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
22. REST OF THE WORLD CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
23. REST OF THE WORLD CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
1. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SHARE BY TYPE, 2019 VS 2026 (%)
2. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
3. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
4. US CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
5. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
6. UK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
7. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
8. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
9. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
10. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
11. ROE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
12. INDIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
13. CHINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
14. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
15. REST OF ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
16. REST OF THE WORLD CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
